Compare Cardinal Health Inc (CAH) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Tesla, Inc. — how do they compare? Cardinal Health Inc trades at $228.18 (market cap $53.89B), while Tesla, Inc. trades at $399 (market cap $1.49T). The key difference: Tesla, Inc. is far larger — about 27.6× Cardinal Health Inc's market cap, and Cardinal Health Inc pays a 0.89% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| CAH | TSLA | |
|---|---|---|
Market Cap | $53.89B | $1.49T |
Sector | Health | Consumer Cyclical |
52-Week High | $239.71 | $489.88 |
52-Week Low | $146.04 | $302.63 |
Enterprise Value | $58.87B | $1.46T |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
Tesla (TSLA) trades at $401.71, up 1.76% on the day, but remains in a bearish technical trend with resistance near $408. The stock shows mixed fundamentals with a high P/E of 363.47 and declining profit margins (3.95% net income margin in 2025), though recent Q1 2026 EPS beat expectations. Cash flow improved to $579M net in 2025, but revenue growth has stalled near $95B. Positive developments include European regulatory approval for self-driving software and a potential cheaper EV launch, per The Motley Fool (April 11, 2026).
Outlook is cautious due to valuation concerns and competitive pressures, but long-term optimism hinges on AI and autonomy breakthroughs. Risks include execution challenges in robotics/energy pivots and volatile sentiment. Analysts are divided with a $409.26 consensus target, suggesting limited upside. Investors should weigh high growth expectations against margin compression and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
